Feature | March 19, 2015

Benefits Seen for First of its Kind Neuro-embolic Protection Shield for TAVR

Device designed to deflect particles dislodged during valve replacement

TriGuard, Keystone, embolic protection, TAVR

The TriGuard embolic protection system prevents debris from valvuloplasty or TAVR valve deployment from traveling to the brain.

March 19, 2015 — An investigational device that deflects debris away from the brain during transcatheter aortic valve replacement (TAVR) seems to improve in-hospital safety outcomes and cognitive scores at discharge, according to preliminary findings from the small, randomized DEFLECT III study presented at the American College of Cardiology (ACC) 2015 Annual Scientific Session. 

TAVR dislodges minute particles from calcified valves that embolize through the bloodstream. Much of this debris travels “downstream” from the heart, but about a quarter of the debris moves “upstream” to the brain, where it can trigger a stroke. These microscopic scraps are a likely contributor to the high stroke rates seen up to a year after TAVR and to the high rates of subclinical brain injury — damage less severe than a stroke that can affect mental functions. 

The Keystone Heart TriGuard device was studied in the DEFLECT III trial. It was designed to reduce the risk of brain damage during TAVR and other procedures that release potentially hazardous debris by covering the three arteries that lead to the brain with a temporary mesh shield. Patients were reviewed after the procedure with diffusion weighted (DW) MRI, which found single and maximum brain lesion volume was reduced by about 40 percent as compared to control patients who did not have TriGuard protection. Based on changes in NIH Stroke Scale, patients protected with TriGuard had 10 percent absolute reduction in stroke (4.9 vs. 14.3 percent).
 
Preliminary data are available for 83 patients with complete in-hospital safety and efficacy measures. Thirty-day data are being gathered and are expected to be reported in May. Target enrollment for the trial is 86 patients recruited from 15 centers in Europe and Israel. 
 
The novel device demonstrated benefit on several endpoints in this small patient population. For in-hospital procedure safety, defined as a hierarchical composite of major adverse cardiovascular and cerebrovascular events up to seven days after TAVR, the rates were 22.2 percent for patients with the device and 31.6 percent for patients in the control group. 
 
Death rates from all causes were 2.2 percent for the device group and 5.3 percent for the control group. For both stroke and life-threatening or disabling bleeding, rates were 2.2 percent for the device group and 5.3 percent for the control group. No safety concerns were seen in two categories: rates of acute kidney injury were 2.2 percent for the device group compared with zero for the control group — one patient vs. none; and rates of major vascular complications were 15.6 percent for the device group and 15.8 percent for the control group. 
 
“Protecting the brain has become a priority to improve our patients’ outcomes, and this is a new focus in interventional cardiology,” said Alexandra Lansky, M.D., director of the Yale Cardiovascular Research Program, Yale School of Medicine and the study’s lead author. DEFLECT III is the first multicenter randomized clinical trial of a brain-protection device.
 
Lansky said patients in the protected group performed better than the control on two cognitive tests, the Montreal Cognitive Assessment, which takes a broad look at all domains of neurocognition, and the Cogstate test, a computerized assessment of mental processing. Diffusion weighted MRI, used as a surrogate endpoint for subclinical brain injury, showed that fewer patients in the device group had new brain lesions and that the volume of the lesions was lower than in the control group. 
 
Patients will be followed for 30 days, and all neurocognition and weighted imaging measures will be repeated at that point to determine whether the early benefits continue. The FDA has approved a definitive Investigational Device Exemption trial called REFLECT, which is expected to start enrollment during the second quarter of 2015. 
 
TriGuard is specifically designed to provide full coverage to all aortic arch takeoffs. The device has CE mark for use in Europe, but is not yet commercially available in the United States.
 
This trial was sponsored by Keystone Heart Ltd.  Lansky has a minor ownership in the company.
 
For more information: acc.org
 

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Montreal Heart Institute Performs First Robotic Mitral Valve Surgery
News | Robotic Systems| September 22, 2017
The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Overlay Init